About: Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine
Creator	Glueck, Reinhard Gupta, Gaurav Giannino, Viviana Rishi, Narayan
source	Elsevier; Medline; PMC
abstract	Abstract Human papillomavirus (HPV) infection is the most common sexually transmitted disease worldwide. HPVs are oncogenic small double-stranded DNA viruses that are the primary causal agent of cervical cancer and other types of cancers, including in the anus, oropharynx, vagina, vulva, and penis. Prophylactic vaccination against HPV is an attractive strategy for preventing cervical cancer and some other types of cancers. However, there are few safe and effective vaccines against HPV infections. Current first-generation commercial HPV vaccines are expensive to produce and deliver. The goal of this study was to develop an alternate potent HPV recombinant L1-based vaccines by producing HPV virus-like particles into a vaccine that is currently used worldwide. Live attenuated measles virus (MV) vaccines have a well-established safety and efficacy record, and recombinant MV (rMV) produced by reverse genetics may be useful for generating candidate HPV vaccines to meet the needs of the developing world. We studied in non-human primate rMV-vectored HPV vaccine in parallel with a classical alum adjuvant recombinant HPV16L1 and 18L1 protein vaccine produced in Pichia pastoris. A combined prime-boost approach using both vaccines was evaluated, as well as immune interference due to pre-existing immunity against the MV. The humoral immune response induced by the MV, Pichia-expressed vaccine, and their combination as priming and boosting approaches was found to elicit HPV16L1 and 18L1 specific total IgG and neutralizing antibody titres. Pre-existing antibodies against measles did not prevent the immune response against HPV16L1 and 18L1.
has issue date	2016-09-07(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2016.07.051
bibo:pmid	27523740
has license	els-covid
sha1sum (hex)	627b268e38efc54e037c978d2b578632b875f44f
schema:url	https://doi.org/10.1016/j.vaccine.2016.07.051
resource representing a document's title	Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine
has PubMed Central identifier	PMC7126718
has PubMed identifier	27523740
schema:publication	Vaccine
resource representing a document's body	covid:627b268e38efc54e037c978d2b578632b875f44f#body_text
is schema:about of	named entity 'MEASLES' named entity 'HPV vaccines' named entity 'HPV VACCINES' named entity 'VECTORED' named entity 'SEXUALLY TRANSMITTED DISEASE' named entity 'INFECTION' covid:arg/627b268e38efc54e037c978d2b578632b875f44f named entity 'HPV VACCINE' named entity 'WORLDWIDE' named entity 'NON-' named entity 'VACCINE' named entity 'HUMAN' named entity 'PROTEIN ' named entity 'IMMUNOGENICITY' named entity 'PICHIA PASTORIS' named entity 'GENERATION' named entity 'HUMAN PAPILLOMAVIRUS ' named entity 'RECOMBINANT PROTEIN' named entity 'PRIMATES' named entity 'COMMON' named entity 'vaccine' named entity 'HPV vaccine' named entity 'HPV vaccines' named entity 'immunogenic' named entity 'Escherichia coli' named entity 'HPV vaccine' named entity 'baculovirus' named entity 'HPV infection' named entity 'vector' named entity 'primer walking' named entity 'Ipswich, MA' named entity 'Gardasil' named entity 'supernatant' named entity 'antigen' named entity 'negative control' named entity 'virus' named entity 'EDTA' named entity 'antibody titres' named entity 'viral vector' named entity 'uranyl acetate' named entity 'recombinant' named entity 'cell line' named entity 'neutralizing antibodies' named entity 'antibody titres' named entity 'antibody titres' named entity 'Plasmid' named entity 'antigens' named entity 'Persistent infections' named entity 'vaccine' named entity 'Cervarix' named entity 'analysis of variance' named entity 'infection' named entity 'major capsid protein' named entity 'cell lysate' named entity 'HPV vaccine' named entity 'PBS' named entity 'nucleocapsid protein' named entity 'Ahmedabad' named entity 'cellular immune responses' named entity 'supernatant' named entity 'expression vector' named entity 'digestion' named entity 'immune response' named entity 'western blotting' named entity 'primates' named entity 'PsV' named entity 'measles' named entity 'HPV' named entity 'HPV' named entity 'viruses' named entity 'monoclonal antibodies' named entity 'transfection' named entity 'HPV vaccine' named entity 'genome' named entity 'HIV' named entity 'cloning' named entity 'neutralizing antibody' named entity 'logistic regression'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software